Clonidine use during dexmedetomidine weaning: A systematic review

Area of Science:

• Pharmacology
• Critical Care Medicine
• Evidence-Based Medicine

Background:

• Dexmedetomidine, an alpha-2A adrenergic agonist, is widely used for sedation in ICUs.
• Prolonged dexmedetomidine use can lead to withdrawal symptoms upon discontinuation.
• Enteral clonidine, another alpha-2A agonist, presents a potential alternative for tapering dexmedetomidine.

Purpose of the Study:

• To systematically review the use of enteral clonidine for weaning patients off dexmedetomidine.
• To evaluate dosing strategies and outcomes associated with this tapering method.
• To identify risk factors for dexmedetomidine withdrawal during clonidine-assisted weaning.

Main Methods:

• Systematic review of randomized controlled trials, prospective cohorts, and retrospective cohorts.
• Included critically ill adults (≥ 18 years) undergoing dexmedetomidine weaning.
• Primary outcomes: enteral clonidine dosing/titration, dexmedetomidine withdrawal risk; Secondary outcomes: adverse events, mechanical ventilation duration, ICU stay.

Main Results:

• Three observational studies with 88 patients were included.
• Enteral clonidine dosing varied, with a common starting dose of 0.3 mg every 6 hours.
• Increased agitation and withdrawal symptoms were observed with enteral clonidine use compared to dexmedetomidine taper alone.

Conclusions:

• Enteral clonidine can be utilized as a strategy for weaning dexmedetomidine in critically ill patients.
• The use of enteral clonidine for tapering is associated with an increased incidence of withdrawal symptoms and agitation.
• Further research is needed to establish optimal dosing and conversion strategies.